Pancreas Neoplasms Clinical Trial
Official title:
Phase II Study: Docetaxel Plus Oxaliplatin as Second-line Therapy in Patients With Advanced Metastatic Pancreatic Cancer
The purpose of this study is to test a combination-therapy of oxaliplatin and docetaxel in patients with metastatic or locally advanced adenocarcinoma of the pancreas after failure of a palliative first line therapy.
For years Fluorouracil was the established treatment for pancreatic cancer with median
survival times up to 8 months. Since 1997 Gemcitabine is also a standard therapy with in
comparison to Fluorouracil a significant better clinical benefit.
But after progression of the disease under a palliative first-line therapy there is no
established second line therapy for pancreatic cancer.
So the purpose of this study is to test the combination of Oxaliplatin and Docetaxel in
patients with metastatic or locally advanced adenocarcinoma of the pancreas after failure of
a palliative first line therapy to get a reasonable second line concept.
;
Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT01774162 -
EUS-guided Fine Needle Biopsy With a New Core Histology Needle Versus Conventional Fine Needle Aspiration
|
N/A | |
Completed |
NCT00930410 -
Intra-ductal Confocal Endomicroscopy for Characterization of Pancreas and Bile Duct Tumor
|
N/A | |
Completed |
NCT00377936 -
EndoTAG-1 / Gemcitabine Combination Therapy to Treat Locally Advanced and/or Metastatic Adenocarcinoma of the Pancreas
|
Phase 2 | |
Terminated |
NCT00198081 -
Use of Celecoxib in Patients With Intraductal Papillary Mucinous Neoplasms (IPMNs)
|
Phase 2 | |
Active, not recruiting |
NCT02905578 -
A Phase 2 Trial of High-dose Ascorbate for Pancreatic Cancer (PACMAN 2.1)
|
Phase 2 | |
Completed |
NCT01446458 -
Phase I Study of Stereotactic Body Radiation Therapy and FOLFIRINOX in the Neoadjuvant Therapy of Pancreatic Cancer
|
Phase 1 | |
Recruiting |
NCT02789371 -
Comparing of Modified Wet Suction Technique and Dry Suction Technique for EUS-FNA of Solid Occupying Lesions
|
N/A | |
Unknown status |
NCT00683358 -
Human Leukocyte Antigen-A*2402-Restricted Tumor Vessel Specific Peptide Vaccination for Advanced Pancreatic Cancer
|
Phase 1/Phase 2 | |
Terminated |
NCT00683085 -
Human Leukocyte Antigen-A*02:01-restricted Tumor Vessel Specific Peptide Vaccination for Advanced Pancreatic Cancer
|
Phase 1/Phase 2 | |
Not yet recruiting |
NCT03803930 -
Comparing of a 22G EUS Procore Fine Needle Biopsy Device and a 20G EUS Procore Fine Needle Biopsy Device
|
N/A | |
Completed |
NCT02681796 -
Epidural Analgesia Use in Pancreatic Resections
|
Phase 1 | |
Recruiting |
NCT02327065 -
Prospective Multi-center, Single Blinded, Randomized, Controlled Trial of EUS-FNB and EUS-FNA on Solid Occupying Lesion
|
N/A | |
Completed |
NCT01693419 -
S-1, Gemcitabine and Erlotinib for Advanced Pancreatic Cancer
|
Phase 2 |